EQ-5D Utilities in Chronic Spontaneous/Idiopathic Urticaria

Emma Hawe, Doreen McBride, Maria-Magdalena Balp, Haijun Tian, Anna Halliday and Donald E. Stull ()
Additional contact information
Emma Hawe: RTI Health Solutions
Doreen McBride: RTI Health Solutions
Maria-Magdalena Balp: Novartis Pharma AG
Haijun Tian: Novartis Pharmaceuticals Corporation
Anna Halliday: Novartis Pharmaceuticals UK Limited
Donald E. Stull: RTI Health Solutions

PharmacoEconomics, 2016, vol. 34, issue 5, No 9, 527 pages

Abstract: Abstract Objectives To obtain utility estimates suitable for use in economic models for chronic spontaneous (idiopathic) urticaria (CSU). Methods Patient-level data from three randomized clinical trials—ASTERIA I, ASTERIA II and GLACIAL—were analysed. Health states were derived from the Urticaria Activity Score over 7 days (UAS7); higher scores denote greater activity. The health state score ranges were urticaria free: 0; well-controlled urticaria: 1–6; mild urticaria: 7–15; moderate urticaria: 16–27; and severe urticaria: 28–42. The mean EQ-5D utilities were calculated for each health state. A mixed model was used to predict the EQ-5D according to UAS7 health states in a pooled data set containing all treatment arms and time points from the three trials. Pooled trial data were validated through visual comparisons and interaction terms. Fixed and random effects for trials and patients were included, along with the following covariates: UAS7 health state at baseline (moderate or severe); presence of angioedema at baseline and during follow-up; duration of CSU; number of previous CSU medications; visit; current treatment; and patient age and sex. Results There was a consistent improvement in EQ-5D utilities as urticaria activity decreased. The mean utilities ranged from 0.710 (severe urticaria) to 0.780 (moderate urticaria), 0.829 (mild urticaria), 0.862 (well-controlled urticaria) and 0.894 (urticaria free). Sensitivity and subgroup analyses confirmed the robustness of the results. Conclusion The results suggest that EQ-5D utility scores increase with decreasing urticaria activity. EQ-5D utility scores enable the health-related quality of life of CSU patients to be compared with that of patients with other diseases.

Date: 2016
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-015-0375-7 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:34:y:2016:i:5:d:10.1007_s40273-015-0375-7

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-015-0375-7

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().